Nalmefene
This medication is used to reduce alcohol consumption in adults who drink heavily, and it works by blocking opioid receptors in the brain that are involved in the rewarding effects of alcohol. It is taken on days when there is a risk of drinking, rather than every day.
Peso Molecular
339,4000 g/mol
LogP
2,70
TPSA
52,90 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Mecanismo de Ação
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …
Estrutura 2D
Cite this structure
Embed this structure
SMILES
C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
InChI
InChI=1S/C21H25NO3/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13/h4-5,13,16,19,23-24H,1-3,6-11H2/t16-,19+,20+,21-/m1/s1
Molecular Formula
C21H25NO3
HBD / HBA
2 / 4
Ligações Rotacionáveis
2
Átomos Pesados
25
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
This medication is used to reduce alcohol consumption in adults who drink heavily, and it works by blocking opioid receptors in the brain that are involved in the rewarding effects of alcohol. It is taken on days when there is a risk of drinking, rather than every day.
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.
Yes, Nalmefene is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL982. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5284594. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="nalmefene"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/nalmefene/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/nalmefene/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/nalmefene/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="nalmefene"></drugfyi-drug>